Inhibition of CD47 Effectively targets pancreatic cancer stem cells via dual mechanisms
Antibodies, Monoclonal, Murine-Derived
Carcinoma, Pancreatic Ductal
Neoplastic Stem Cells
These data are consistent with efficient in vivo targeting of CSCs, and strongly suggest that CD47 inhibition could be a novel adjuvant treatment strategy for PDAC independent of underlying and highly variable driver mutations.